Article Text

PDF
Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema
  1. Hemal Mehta1,2,
  2. Samantha Fraser-Bell1,
  3. Vuong Nguyen1,
  4. Lyndell L Lim3,
  5. Mark C Gillies1
  1. 1The Save Sight and Eye Health Institute, Sydney Medical School, University of Sydney, Sydney, Australia
  2. 2The Royal Free London NHS Foundation Trust, London, UK
  3. 3Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia
  1. Correspondence to Dr Hemal Mehta, Macula Research Group, The Save Sight and Eye Health Institute, University of Sydney, 8 Macquarie Street, Sydney, NSW 2000, Australia; HM{at}cantab.net

Abstract

Aim To determine whether early vision gains predict long-term visual outcomes in the BEVORDEX randomised clinical trial of bevacizumab or dexamethasone implants for diabetic macular oedema.

Methods Post hoc analysis of 68 study eyes (77%) that completed 2 years follow-up of the BEVORDEX multicentre randomised clinical trial set in Australia (ClinicalTrials.gov identifier: NCT01298076). Study eyes from both groups were combined and stratified by visual acuity (VA) change in the first 12 weeks in to three groups: (a) suboptimal gain: <5 letters gain (includes VA loss), (b) moderate gain: 5–9 letters gain, (c) pronounced gain: ≥10 letters gain. This was correlated with VA outcome at 104 weeks taking into account treatment allocation and baseline lens status.

Results The change in VA in the first 12 weeks was significantly correlated with VA change at 104 weeks (p<0.001). This was independent of treatment allocation (p=0.353) and lens status at baseline (p=0.593). The change in central macular thickness at 12 weeks did not correlate with VA gain at 104 weeks (p=0.847).

Conclusion Short-term visual gain at 12 weeks was strongly correlated with long-term vision improvement independent of treatment allocation or baseline lens status. Early improvement in central macular thickness was not predictive of long-term visual outcomes.

Trial registration number NCT01298076, Post-results.

  • diabetic macular oedema
  • steroid
  • dexamethasone
  • bevacizumab

Statistics from Altmetric.com

Footnotes

  • Contributors Study concept and design: All authors. Acquisition, analysis, or interpretation of data: HM, VN, MCG. Drafting of the manuscript: HM, VN. Critical revision of the manuscript for important intellectual content: MCG, SF-B, LLL. Obtained funding: All authors. Administrative, technical or material support: HM, VN, MCG. Study supervision: MCG, SF-B, LLL.

  • Funding This study was funded by a project grant from the National Health and Medical Research Council (NHMRC) Australia, which was supplemented by unrestricted educational grants from Allergan Pharmaceuticals and Alimera Sciences. MCG is a Sydney Medical School Foundation Fellow and is supported by an NHMRC Clinical Practitioner Fellowship. The funding bodies had no influence on the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript; and decision to submit for publication.

  • Competing interests None declared.

  • Ethics approval This study was approved by the Human Research Ethics Committees of Sydney South West Area Health Service, the University of Sydney, the Royal Victorian Eye and Ear Hospital, and Bellberry.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.